Evaluate AGIO stock safety — financial health, volatility, institutional backing, and risk factors.

What are the risks of investing in AGIO? | Glauxie AI

Q: What are the risks of investing in AGIO?

Agios Pharmaceuticals, Inc. (AGIO) operates in the Biotechnology industry (Healthcare sector). The company is led by CEO Brian Goff. Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers... Employees: 539.

Q: How much debt does AGIO have?

Review AGIO total debt, debt-to-equity ratio, interest coverage, and leverage trends.

Q: Is AGIO a good long-term investment?

Evaluate AGIO as a long-term investment using fundamental scores, growth metrics, and risk assessment.

What are the risks of investing in AGIO?

🦉

Agios Pharmaceuticals, Inc. (AGIO)

Company Overview

Sector / IndustryHealthcare / Biotechnology

CEOBrian Goff

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK,...

Key Executives

Name	Title
Brian Goff	Chief Executive Officer & Director
Cecilia Jones	Chief Financial Officer
Clive Patience	Chief Technical Operations Officer
Craig Thompson	Co-Founder
James William Burns	Chief Legal Officer
Krishnan Viswanadhan	Chief Corporate Development & Strategy Officer

Financial Health

Risk Assessment

Weather Score0/100

RegimeN/A

AGIO Profile Financials

Is AGIO stock safe? How much debt does AGIO have? Is AGIO a good long-term investment?